Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel to Chemotherapy plus Trastuzumab in

 


NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel to Chemotherapy plus Trastuzumab in


Trial Focus

Breast Cancer

Objective

         This is a clinical trial comparing two different standard chemotherapy treatments administered by IV with and without the drug trastuzumab. Trastuzumab will be administered by IV and is investigational.

IRB Protocol #

13-0163

Trial Status

Archived

Principle Investigator

NICOLE KOUNALAKIS

Sponsor

NSABP

Contact

BRITTANY HICKS at (720)848-0657 or BRITTANY.HICKS@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period(s) that can last as long as a year. A follow-up period that can last until it has been 10 years from the date one joins the study. // Eligibility criteria include but are not limited to 18 years or older with breast cancer.Eligibility criteria include but are not limited to 18 years or older with breast cancer.